These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 10081492)

  • 1. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
    Naoe Y; Inami M; Matsumoto S; Takagaki S; Fujiwara T; Yamazaki S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
    Jpn J Cancer Res; 1998 Dec; 89(12):1306-17. PubMed ID: 10081492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of FK317 on multidrug-resistant tumor in vivo and in vitro.
    Naoe Y; Inami M; Takagaki S; Matsumoto S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
    Jpn J Cancer Res; 1998 Oct; 89(10):1047-54. PubMed ID: 9849584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon26 and LX-1 models in mice.
    Naoe Y; Kawamura I; Inami M; Matsumoto S; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
    Jpn J Cancer Res; 1998 Dec; 89(12):1318-25. PubMed ID: 10081493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome.
    Naoe Y; Inami M; Matsumoto S; Nishigaki F; Tsujimoto S; Kawamura I; Miyayasu K; Manda T; Shimomura K
    Cancer Chemother Pharmacol; 1998; 42(1):31-6. PubMed ID: 9619755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T; Müller M; Monia BP; Fabbro D
    Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
    Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
    Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
    Kudoh S; Takada M; Masuda N; Nakagawa K; Itoh K; Kusunoki Y; Negoro S; Matsui K; Takifuji N; Morino H
    Jpn J Cancer Res; 1993 Feb; 84(2):203-7. PubMed ID: 8385085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.
    Manzotti C; Pratesi G; Menta E; Di Domenico R; Cavalletti E; Fiebig HH; Kelland LR; Farrell N; Polizzi D; Supino R; Pezzoni G; Zunino F
    Clin Cancer Res; 2000 Jul; 6(7):2626-34. PubMed ID: 10914703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of FK317, a novel anti-cancer agent, on survival of mice bearing B16BL6 melanoma and Lewis lung carcinoma.
    Inami M; Kawamura I; Tsujimoto S; Nishigaki F; Matsumoto S; Naoe Y; Sasakawa Y; Matsuo M; Manda T; Goto T
    Cancer Lett; 2002 Jul; 181(1):39-45. PubMed ID: 12430177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
    Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
    Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
    Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
    Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic mechanisms of FK317, a new class of bioreductive agent with potent antitumor activity.
    Naoe Y; Inami M; Kawamura I; Nishigaki F; Tsujimoto S; Matsumoto S; Manda T; Shimomura K
    Jpn J Cancer Res; 1998 Jun; 89(6):666-72. PubMed ID: 9703365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
    Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
    Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
    Nakanishi O; Baba M; Saito A; Yamashita T; Sato W; Abe H; Fukazawa N; Suzuki T; Sato S; Naito M; Tsuruo T
    Oncol Res; 1997; 9(2):61-9. PubMed ID: 9167187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
    Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
    Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new antitumor antibiotic, FR900840. III. Antitumor activity against experimental tumors.
    Nishimura M; Nakada H; Kawamura I; Mizota T; Shimomura K; Nakahara K; Goto T; Yamaguchi I; Okuhara M
    J Antibiot (Tokyo); 1989 Apr; 42(4):553-7. PubMed ID: 2542208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
    Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
    Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.